Lindsey E Scierka
Overview
Explore the profile of Lindsey E Scierka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
23
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cleman J, Romain G, Scierka L, Labrosciano C, Bradley B, Fitridge R, et al.
Vasc Med
. 2024 Sep;
29(6):664-674.
PMID: 39319857
Background: Healthcare utilization for patients with peripheral artery disease (PAD) is high, but stratifying patients' risk of hospitalization at initial evaluation is challenging. We examined the association between health status...
2.
Scierka L, Cleman J, Brice A, Grimshaw A, Soedamah-Muthu S, Mena-Hurtado C, et al.
Eur J Vasc Endovasc Surg
. 2024 Aug;
68(6):771-783.
PMID: 39216793
Objective: Nutritional status plays a complex role in the pathophysiology and outcomes of chronic limb threatening ischaemia (CLTI). Undernutrition may be a modifiable risk factor. Given the variability in nutritional...
3.
Romain G, Wang K, Scierka L, Cleman J, Callegari S, Aboian E, et al.
J Vasc Surg
. 2024 May;
80(3):737-745.e14.
PMID: 38729585
Background: Variation in the care management of repairs for ruptured infrarenal abdominal aortic aneurysms between centers and physicians, such as procedural volumes, may explain differences in mortality outcomes. First, we...
4.
Regan C, Scierka L, Dardik A, Tonnessen B, Ochoa Chaar C, Ionescu C, et al.
Vascular
. 2024 Apr;
:17085381241246318.
PMID: 38669051
Objectives: Antiplatelet therapy is an essential element in the management of patients with arterial vascular disease. In peripheral arterial disease (PAD), dual antiplatelet therapy (DAPT), primarily clopidogrel and aspirin, is...
5.
Scierka L, Bradley B, Glynn E, Davis S, Hoffman M, Tam-Williams J, et al.
J Healthc Inform Res
. 2024 Jan;
8(1):50-64.
PMID: 38273985
Chronic cough is a common condition; until recently, no International Classification of Diseases (ICD) code for chronic cough existed; therefore, the true scope and burden of chronic cough is unclear....
6.
Scierka L, Peri-Okonny P, Romain G, Cleman J, Spertus J, Fitridge R, et al.
J Vasc Surg
. 2024 Jan;
79(6):1473-1482.e5.
PMID: 38266885
Background: As a key treatment goal for patients with symptomatic peripheral artery disease (PAD), improving health status has also become an important end point for clinical trials and performance-based care....
7.
Scierka L, Peri-Okonny P, Romain G, Mena-Hurtado C, Smolderen K
Obes Res Clin Pract
. 2023 May;
17(3):264-268.
PMID: 37225553
Obesity has been associated with poor disease outcomes in patients with lower extremity peripheral arterial disease (PAD). Given evolving treatments for obesity, evaluating its prevalence and treatment practices are key...
8.
Smolderen K, Romain G, Provance J, Scierka L, Mao J, Goodney P, et al.
JACC Cardiovasc Interv
. 2023 Feb;
16(3):332-343.
PMID: 36792257
Background: Lack of guideline-directed medical therapy (GDMT) in patients undergoing peripheral vascular interventions (PVIs) may increase mortality and amputation risk. Objectives: The authors sought to study the association between GDMT...
9.
Scierka L, Mena-Hurtado C, Ahmed Z, Yousef S, Arham A, Grimshaw A, et al.
J Affect Disord
. 2022 Sep;
320:169-177.
PMID: 36179780
Background: Peripheral artery disease (PAD) is highly prevalent and associated with poor outcomes. Depression is a risk factor for adverse outcomes in patients with coronary artery disease. Despite evidence showing...
10.
Nagpal S, Scierka L, Castro-Dominguez Y, Kansal D, Kunnirickal S, Hussain Y, et al.
Catheter Cardiovasc Interv
. 2022 Sep;
100(5):776-784.
PMID: 36129818
Background: The VASCADE closure device deploys an extravascular collagen plug. Its use in those with access site disease undergoing peripheral vascular intervention (PVI) is unknown. We aimed to evaluate the...